dalteparin has been researched along with Acute Kidney Failure in 22 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " She also developed right proximal femoral deep vein thrombosis, and was commenced on subcutaneous enoxaparin and warfarin." | 3.88 | Dengue shock syndrome complicated with acute liver failure and kidney injury, infective endocarditis, and deep vein thrombosis: a case report. ( Munasinghe, J; Samarasekara, K, 2018) |
| "Dalteparin-treated patients received a commencement bolus of 20 units/kg and a maintenance infusion at 10 units/kg/hr." | 2.69 | A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. ( Cumming, AR; Gallagher, L; O'Brien, JL; Reeves, JH; Santamaria, JD, 1999) |
| " In hemodialysis patients, enoxaparin at once daily reduced dosing should be considered with trough and peak anti-Xa levels monitoring." | 1.62 | Management of Anticoagulation Therapy in Patients With Thromboembolism in the Context of Renal Dysfunction: Challenging Cases and Practical Algorithms. ( Bahabri, A; Belostosky, V; Bhatt, MD; Chan, AKC, 2021) |
| "Leptospirosis is an acute generalized infectious disease, caused by spirochaetes, Leptospira interrogans." | 1.33 | Three cases of anicteric leptospirosis from Turkey: mild to severe complications. ( Demiroz, AP; Erdinc, FS; Hatipoglu, CA; Kinikli, S; Koruk, ST, 2006) |
| " In addition, we review the use of LMWH in renal insufficiency, dosing in obese patients,and the importance of sulfate content in the efficacy of protamine sulfate as a reversing agent for LMWH." | 1.32 | Incomplete reversal of enoxaparin toxicity by protamine: implications of renal insufficiency, obesity, and low molecular weight heparin sulfate content. ( Chawla, LS; Moore, G; Seneff, MG, 2004) |
| "During all low-dose treatments, marked thrombus formation occurred in the extracorporeal circuit, and in 2, the circuit clotted within the study period." | 1.29 | Anticoagulation with low molecular weight heparin (Fragmin) during continuous hemodialysis in the intensive care unit. ( Davison, AM; Douglas, JT; Jeffrey, RF; Khan, AA; Will, EJ, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 7 (31.82) | 29.6817 |
| 2010's | 10 (45.45) | 24.3611 |
| 2020's | 3 (13.64) | 2.80 |
| Authors | Studies |
|---|---|
| Eck, RJ | 1 |
| van de Leur, JJCM | 1 |
| Wiersema, R | 1 |
| Cox, EGM | 1 |
| Bult, W | 1 |
| Spanjersberg, AJ | 1 |
| van der Horst, ICC | 1 |
| Lukens, MV | 1 |
| Gans, ROB | 1 |
| Meijer, K | 1 |
| Keus, F | 1 |
| Buter, H | 1 |
| Koopmans, M | 2 |
| van der Voort, PHJ | 1 |
| Oudemans-van Straaten, HM | 2 |
| Bosman, RJ | 1 |
| van der Voort, PH | 2 |
| Wester, JP | 2 |
| van der Spoel, JI | 1 |
| Dijksman, LM | 1 |
| Zandstra, DF | 1 |
| van Schilfgaarde, M | 1 |
| Molenaar, PJ | 1 |
| Leyte, A | 1 |
| Zhang, W | 1 |
| Chen, X | 1 |
| Chen, Y | 1 |
| Chen, N | 1 |
| Postma, SR | 1 |
| Kingma, WP | 1 |
| Boerma, EC | 1 |
| de Heide, LJ | 1 |
| Bakker, AJ | 1 |
| Schneiter, S | 1 |
| Huynh-Do, U | 1 |
| Heizmann, M | 1 |
| Faour, WH | 1 |
| Choaib, A | 1 |
| Issa, E | 1 |
| Choueiry, FE | 1 |
| Shbaklo, K | 1 |
| Alhajj, M | 1 |
| Sawaya, RT | 1 |
| Harhous, Z | 1 |
| Alefishat, E | 1 |
| Nader, M | 1 |
| Bahabri, A | 1 |
| Chan, AKC | 1 |
| Belostosky, V | 1 |
| Bhatt, MD | 1 |
| Samarasekara, K | 1 |
| Munasinghe, J | 1 |
| Mooney, T | 1 |
| Joseph, P | 1 |
| Robinson, S | 1 |
| Zincuk, A | 1 |
| Larsen, UL | 1 |
| Ekstrøm, C | 1 |
| Toft, P | 1 |
| Garcés, EO | 1 |
| Victorino, JA | 1 |
| Thomé, FS | 1 |
| Röhsig, LM | 1 |
| Dornelles, E | 1 |
| Louzada, M | 1 |
| Stifft, J | 1 |
| de Holanda, F | 1 |
| Veronese, FV | 1 |
| Mir, T | 1 |
| Layliev, J | 1 |
| Glickman, LT | 1 |
| Chawla, LS | 1 |
| Moore, G | 1 |
| Seneff, MG | 1 |
| Erdinc, FS | 1 |
| Koruk, ST | 1 |
| Hatipoglu, CA | 1 |
| Kinikli, S | 1 |
| Demiroz, AP | 1 |
| Rachmani, R | 1 |
| Levi, Z | 1 |
| Zissin, R | 1 |
| Bernheim, J | 1 |
| Korzets, Z | 1 |
| Bauersachs, R | 1 |
| Schellong, SM | 1 |
| Haas, S | 1 |
| Tebbe, U | 1 |
| Gerlach, HE | 1 |
| Abletshauser, C | 1 |
| Sieder, C | 1 |
| Melzer, N | 1 |
| Bramlage, P | 1 |
| Riess, H | 1 |
| Wu, B | 1 |
| Zhang, K | 1 |
| Xu, B | 1 |
| Ji, D | 1 |
| Liu, Z | 1 |
| Gong, D | 1 |
| Uljas, E | 1 |
| Karjalainen, M | 1 |
| Vaara, S | 1 |
| Reinikainen, M | 1 |
| Jeffrey, RF | 1 |
| Khan, AA | 1 |
| Douglas, JT | 1 |
| Will, EJ | 1 |
| Davison, AM | 1 |
| Reeves, JH | 1 |
| Cumming, AR | 1 |
| Gallagher, L | 1 |
| O'Brien, JL | 1 |
| Santamaria, JD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration, a Randomized Controlled Trial Comparing Anticoagulation With Citrate to the Low Molecular Weight Heparin Nadroparin[NCT00286273] | Phase 4 | 215 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Simplified Regional Citrate Anticoagulation Protocols for CVVH, CVVHDF and SLED Focused on the Prevention of RRT-related Hypophosphatemia and Optimization of Acid-base Balance: a Pilot Study[NCT03976440] | 30 participants (Anticipated) | Observational | 2019-06-01 | Active, not recruiting | |||
| Nadroparin Anticoagulation for Continuous Venovenous Hemofiltration (CVVH), a Randomized Cross-over Trial Comparing Hemostasis Between Two Hemofiltration Rates[NCT00965328] | Phase 4 | 14 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| A Randomized, Double-blind, Multi-center Comparison of the Efficacy and Safety of Certoparin (3000 U Anti-Xa o.d.) With Unfractionated Heparin (5000 IU t.i.d.) in the Prophylaxis of Thromboembolic Events in Acutely Ill Medical Patients[NCT00451412] | Phase 3 | 3,254 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for dalteparin and Acute Kidney Failure
| Article | Year |
|---|---|
Clinical experience with nadroparin in patients undergoing dialysis for renal impairment.
Topics: Acute Kidney Injury; Anticoagulants; Female; Hemorrhage; Humans; Male; Nadroparin; Practice Guidelin | 2011 |
Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies.
Topics: Acute Kidney Injury; Aldosterone; Angiotensins; Antibodies, Monoclonal, Humanized; Autopsy; Biopsy; | 2022 |
8 trials available for dalteparin and Acute Kidney Failure
| Article | Year |
|---|---|
Citrate anticoagulation for continuous venovenous hemofiltration.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Critical Illness; Female; Hemofiltration; He | 2009 |
Citrate anticoagulation for continuous venovenous hemofiltration.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Critical Illness; Female; Hemofiltration; He | 2009 |
Citrate anticoagulation for continuous venovenous hemofiltration.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Critical Illness; Female; Hemofiltration; He | 2009 |
Citrate anticoagulation for continuous venovenous hemofiltration.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Critical Illness; Female; Hemofiltration; He | 2009 |
Hemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration: a randomized cross-over trial comparing two hemofiltration rates.
Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; APACHE; Blood Coagulation; Critical Illness; Cross | 2009 |
An observational study on the effects of nadroparin-based and citrate-based continuous venovenous hemofiltration on calcium metabolism.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Calcium Citrate; Chelating Agents; Citrates; Cri | 2007 |
A feasible strategy for preventing blood clots in critically ill patients with acute kidney injury (FBI): study protocol for a randomized controlled trial.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Adult; Anticoagulants; Critical Illness; Double-Blind Met | 2014 |
Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial.
Topics: Acute Kidney Injury; Anticoagulants; Enoxaparin; Heparin; Humans; Partial Thromboplastin Time; Renal | 2010 |
CERTIFY: prophylaxis of venous thromboembolism in patients with severe renal insufficiency.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Anticoagulants; Female; Germany; Hemorrhage; Heparin; | 2011 |
Randomized Controlled Trial to Evaluate Regional Citrate Anticoagulation Plus Low-Dose of Dalteparin in Continuous Veno-Venous Hemofiltration.
Topics: Acute Kidney Injury; Adult; Anticoagulants; Blood Coagulation; Citric Acid; Dalteparin; Female; Hemo | 2015 |
A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration.
Topics: Acute Kidney Injury; Adult; Anticoagulants; Cost-Benefit Analysis; Dalteparin; Hemofiltration; Hemog | 1999 |
12 other studies available for dalteparin and Acute Kidney Failure
| Article | Year |
|---|---|
Trough anti-Xa activity after intermediate dose nadroparin for thrombosis prophylaxis in critically ill patients with COVID-19 and acute kidney injury.
Topics: Acute Kidney Injury; Anticoagulants; COVID-19; Critical Illness; Humans; Nadroparin; Prospective Stu | 2022 |
Strong ion difference and CVVH: Different response during nadroparin versus citrate anticoagulation.
Topics: Acute Kidney Injury; Adult; Aged; Anesthesia; Anions; Anticoagulants; APACHE; Blood Coagulation; Cit | 2018 |
[Bleeding complication due to accumulation of low-molecular-weight heparin in a patient with renal insufficiency].
Topics: Acute Kidney Injury; Adolescent; Age Factors; Aged; Anticoagulants; Anuria; Child; Creatinine; Enoxa | 2007 |
Management of Anticoagulation Therapy in Patients With Thromboembolism in the Context of Renal Dysfunction: Challenging Cases and Practical Algorithms.
Topics: Acute Kidney Injury; Algorithms; Anticoagulants; Child; Child, Preschool; Drug Monitoring; Enoxapari | 2021 |
Dengue shock syndrome complicated with acute liver failure and kidney injury, infective endocarditis, and deep vein thrombosis: a case report.
Topics: Acute Kidney Injury; Adult; Anticoagulants; Coinfection; Dengue; Endocarditis, Bacterial; Enoxaparin | 2018 |
Purple toes syndrome following stroke thrombolysis and warfarin therapy.
Topics: Acute Kidney Injury; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Embolism, Cholesterol; | 2014 |
Massive spontaneous hematoma from chronic enoxaparin (Lovenox) use.
Topics: Abdominal Wall; Acute Kidney Injury; Anticoagulants; Combined Modality Therapy; Disease Progression; | 2010 |
Incomplete reversal of enoxaparin toxicity by protamine: implications of renal insufficiency, obesity, and low molecular weight heparin sulfate content.
Topics: Acute Kidney Injury; Anastomosis, Surgical; Anticoagulants; Cholecystectomy; Comorbidity; Enoxaparin | 2004 |
Three cases of anicteric leptospirosis from Turkey: mild to severe complications.
Topics: Acute Kidney Injury; Acyclovir; Adult; Aged; Agglutination Tests; Ampicillin; Anti-Bacterial Agents; | 2006 |
Acute renal failure and paraplegia in a patient with a pelvic-ring fracture.
Topics: Acute Kidney Injury; Anticoagulants; Enoxaparin; Fractures, Bone; Hematoma; Humans; Hydronephrosis; | 2000 |
[Anticoagulation for continuous renal replacement therapy in the intensive care unit: a comparison of dalteparin infusion with regional citrate anticoagulation].
Topics: Acute Kidney Injury; Anticoagulants; Calcium; Citrates; Dalteparin; Humans; Intensive Care Units; Re | 2015 |
Anticoagulation with low molecular weight heparin (Fragmin) during continuous hemodialysis in the intensive care unit.
Topics: Acute Kidney Injury; Adult; Aged; Blood Coagulation; Critical Care; Dalteparin; Female; Fibrinopepti | 1993 |